We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dispensability of Annual Laboratory Follow-Up After More than 2 Years of Valproic Acid Use: A Systematic Review.
- Authors
Meijboom, Rosanne; Grootens, Koen; Meijboom, Rosanne W; Grootens, Koen P
- Abstract
<bold>Background: </bold>The necessity of annual laboratory follow-up in patients treated with valproic acid (VPA) is controversial.<bold>Objective: </bold>We investigated the need for annual laboratory follow-up of liver enzymes, electrolytes, and full blood count (FBC) in patients treated with VPA.<bold>Patients and Methods: </bold>A systematic search in Evidence-Based Medicine Reviews (EBMR), MEDLINE, and EMBASE was undertaken in December 2016 to identify all published articles investigating or citing valproic acid, liver function disorders, electrolyte disorders, and FBC deviations.<bold>Results: </bold>This review included 108 articles. As the number of participants and duration of the study was not adequate in most studies to detect rare adverse events, studies did not demonstrate a clear prevalence of hepatotoxicity. While a transient increase of transaminases is common and seldom harmful, severe hepatotoxicity is a rare phenomenon and is not prevented by routine laboratory monitoring. VPA had no relevant effect on serum calcium, sodium, potassium, and albumin. The prevalence of FBC varied from 0.6 to 27.8%, occurred mostly in the first 2 years of therapy, and was usually asymptomatic.<bold>Conclusions: </bold>Long-term monitoring in VPA treatment is only necessary when there have been dose adjustments, co-medication switches, or co-morbidity. In uncomplicated cases, annual laboratory follow-up may be discontinued after 2 years of VPA treatment. Encouraging patients to be vigilant is more effective in the detection of hepatotoxicity than laboratory testing. Follow-up of FBC at 3-6 months, 1 year, and 2 years after start or after a dose increase of VPA or interacting medication is sufficient.
- Subjects
VALPROIC acid; LIVER enzymes; ELECTROLYTES; BLOOD cell count; MEDLINE; AMINOTRANSFERASES; ANTICONVULSANTS; CLINICAL pathology; DRUG monitoring; DRUG side effects; LONGITUDINAL method; TIME; SYSTEMATIC reviews; EVIDENCE-based medicine; PROFESSIONAL practice; ROUTINE diagnostic tests
- Publication
CNS Drugs, 2017, Vol 31, Issue 11, p939
- ISSN
1172-7047
- Publication type
journal article
- DOI
10.1007/s40263-017-0479-z